Clinical trials: Necrotizing Fasciitis
Full-thickness Skin Defects, Degloving Injuries
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
- Conditions
- Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin
- Trial name
- NCT04091672
- Testing
- Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- Avita Medical
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Daptomycin is a new antimicrobial agent which has activity against resistant Gram positive cocci including MRSA. The phase 3 clinical trials for skin and soft tissue infections (SSTI) with Staphylococci and Streptococci have…
- Conditions
- Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
- Trial name
- NCT00261807
- Testing
- Daptomycin 6mg/kg/day
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Necrotizing Fasciitis
Hyperglycemia in Surgical Infections
The primary purpose of this study is to evaluate two glycemic control regimens on clinical outcome in patients with necrotizing soft tissue infections.
- Trial name
- NCT00353275
- Testing
- Strict Glycemic control, Conventional Glycemic Control
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Health Science Center, Houston
Necrotizing Soft Tissue Infections, Necrotizing Fasciitis
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections (NSTI) receiving standard of care therapy.
- Conditions
- Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene
- Trial name
- ACCUTE (NCT02469857)
- Testing
- AB103 0.5 mg/kg, NaCl 0.9%
- Where
- 71 sites in United States, France
- Volunteers
- 290 people
- Sponsor
- Atox Bio Ltd